Drugs / ECLUTATUG
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06054477 | Oct 2023 → Feb 2025 | head and neck squamous cell carcinoma | Alentis Therapeutics AG | Terminated | No outcome recorded |
News releases announcing trial results or a regulatory action · 5
| Date | Issuer | Release |
|---|---|---|
| 2023-08-24 | Alentis Therapeutics AG | Regulatory Alentis Therapeutics Receives FDA Fast Track Designation for ALE.C04 for the Treatment of Claudin-1 Positive HNSCC alentis.ch ↗
Alentis Therapeutics (“Alentis”), a clinical-stage biotechnology company developing treatments for Claudin-1 positive (CLDN1+) tumors and organ fibrosis, announced today that the US Food and Drug Administration (FDA) has granted Fast Track development program for ALE.C04 for the treatment of patients with recurrent or metastatic, CLDN1-positive HNSCC. |
| 2023-06-14 | Alentis Therapeutics AG | Regulatory Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors alentis.ch ↗
The IND clearance for ALE.C04 is an important step for Alentis as it marks our entry into the oncology space. |
| 2023-04-14 | Alentis Therapeutics AG | Results ALENTIS TO PRESENT DATA AT AACR alentis.ch ↗
The poster session entitled, CLAUDIN-1 targeting antibody ALE.C04 drives single agent activity and restores anti-PD1 efficacy in solid tumors, presents evidence that ALE.C04 is a highly specific humanized monoclonal antibody that recognizes a unique CLDN1-exposed epitope in different solid tumors. |
| 2022-12-01 | Alentis Therapeutics AG | Results Alentis to Present Data at ESMO Immuno-Oncology Congress showing Claudin-1 Targeting Antibody ALE.C04 Restored T-cell Infiltration and Checkpoint Inhibitor Efficacy in Pre-clinical Mouse Tumor Model alentis.ch ↗
Importantly, the use of non-junctional Claudin-1-targeting monoclonal antibody ALE.C04 restored T-cell infiltration and CPI efficacy in a pre-clinical mouse tumor model. |
| 2022-11-02 | Alentis Therapeutics AG | Results Article published in The Journal of Hepatology highlights potential of Claudin-1 as a novel target for the treatment of hepatocellular carcinoma alentis.ch ↗
The study found that mAbs targeting CLDN1 inhibit tumor growth in patient-derived ex vivo and in vivo models by modulating signaling, cell stemness and the tumor immune microenvironment. |
All press releases naming this drug 6 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ECLUTATUG | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068235 ↗ |
| Known as | ALE.C04 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06054477 ↗ |
| Modality | Monoclonal antibody | — CHEMBL6068235 ↗ |